The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
LRRK2 Target Engagement Ligand, 2011Evaluating Novel Small Molecule Inhibitors of LRRK2 to Deliver PET Ligands
Objective/Rationale:
The exciting discovery of activating mutations in the LRRK2 kinase in familial PD patients, coupled with the emergence of kinase inhibitors as a new class of efficacious drugs... -
Rapid Response Innovation Awards, 2011Developing a Human Neural Model for Parkinson's Disease
Objective/Rationale:
Advances in the knowledge and treatment of Parkinson’s disease (PD) are limited by the inability to obtain, grow and study neural cells from the brains of living patients. Small... -
MJFF Research Grant, 2011Development and Test of a P25a Competitive Alpha-synuclein Aggregate Binding Assay and Test of Thioflavin-T as Competitor
Objective/Rationale:
Compounds targeting aggregated alpha-synuclein are high in demand as potential bio-imaging tools. We have previously developed an assay that measures the binding of the protein... -
MJFF Research Grant, 2011Just in Time Pre-clinical Resource for Evaluating Symptoms & Side Effects and/or Dyskinesia Treatments
Objective/Rationale:
There is a clear need for the development of novel treatments to better manage the symptoms of Parkinson’s disease. While current treatments address some of the motor symptoms of... -
MJFF Research Grant, 2011Generation of Synthetic Alpha-synuclein for the PD Research Community
Objective/Rationale:
Despite increasing evidence linking specific modifications to alpha-synuclein (alpha-syn), alpha-synuclein aggregation, and Lewy body (LB) formation, little is still known... -
LRRK2 Target Engagement Ligand, 2011Discovery of LRRK2 Target Engagement Ligands to be Used in Imaging Studies
Objective/Rationale:
LRRK2 is an emerging target for discovery of a neuroprotective agent for treatment of PD. Multiple mutations within the LRRK2 gene are associated with PD and many of these have...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.